drugset / Trial / NCT05684380

Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)

NCT05684380

Phase 3 Unknown 514 enrolled EMS
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of MAZ-101 in the treatment of moderate-severe persistent allergic rhinitis.

Timeline

Start
2024-09
Primary completion
2024-11
Completion
2025-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator DYMISTA® Unknown
Subject MAZ-101association Unknown

Indications